U.S. License Holder:
Accord BioPharma
Date of License:
May-07-2026
Last Update:
July-08-2026
FDA-Approved Indications
ENNUMO (pegfilgrastim-pccg) is a leukocyte growth factor indicated in adults and pediatric patients aged newborn and older to:
Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia;
Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).
Approved Foreign Follow-On Biologics / Biosimilars
Biosimilars Approved In The E.U.
Pelgraz (Accord Healthcare) (September-2018)
